This is the fourth of the abstracts for talks being given at the 1st Eagle Genomics Symposium, "Provisioning Bioinformatics for the Next Decade - are we prepared?". This week we'll hear from Matt Hall, UK Team Leader Computational Biology for GSK. Matt's talk is entitled "The current state of bioinformatics in a big pharma company."
Here is Matt's abstract:
"The pharmaceutical industry is going through major changes. Many significant medicines are losing patent protection over the next few years and with them loss of revenues. There are increased pressures from regulators for ever safer medicines and the payers will only reimburse for new medicines which have significant benefits over existing treatments. Pharmaceutical R&D organisations have failed to deliver the new medicines as promised by the genomics revolution. Against this backdrop there have been major restructuring in bioinformatics groups within pharmaceutical companies. The talk will touch on some of these changes that have occurred over the last 10 years and provide examples of the current types of work and challenges faced by a central group providing bioinformatics analysis support within a large pharma company."
If you're interested in what Matt and our other speakers have to say, why not sign up and come along!
Remember that early-bird discounts on registration are only available until Feb 28th!